Advances in Molecular Characterization and Targeted Therapy in Dermatofibrosarcoma Protuberans

Table 1

The best overall responses, progression, and survival status in combined phase II clinical trials [55] and in group of patients treated outside clinical trials [56].

	Group of 24 patients treated in phase II trials [55]	Group of 15 patients treated outside clinical trials [56]
	N (%)
Progression status
Progression-free	12 (50)	11 (73)
Progression	12 (50)	4 (27)
Survival status
Alive	18 (75)	12 (80)
Dead	6 (25)	3 (20)
Best overall response
Partial response	11 (45.9)	11 (73)
Stable disease	6 (25)	1 (7)
Progressive disease	4 (16.6)	3 (20)
Not evaluable	3 (12.5)	0